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6¢ ,7¢ -Dihydroxybergamottin in grapefruit
juice and Seville orange juice: Effects on
cyclosporine disposition, enterocyte
CYP3A4, and P-glycoprotein
Background: 6¢ ,7¢ -Dihydroxybergamottin is a furanocoumarin that inhibits CYP3A4 and is found in grape-
fruit juice and Seville orange juice. Grapefruit juice increases the oral bioavailability of many CYP3A4
substrates, including cyclosporine (INN, ciclosporin), but intestinal P-glycoprotein may be a more impor-
tant determinant of cyclosporine availability.
Objectives: To evaluate the contribution of 6¢ ,7 ¢ -dihydroxybergamottin to the effects of grapefruit juice on
cyclosporine disposition and to assess the role of CYP3A4 versus P-glycoprotein in this interaction.
Methods: The disposition of oral cyclosporine was compared in healthy subjects after ingestion of water,
grapefruit juice, and Seville orange juice. Enterocyte concentrations of CYP3A4 were measured in 2 indi-
viduals before and after treatment with Seville orange juice. The effect of 6 ¢ ,7 ¢ -dihydroxybergamottin on
P-glycoprotein was assessed in vitro.
Results: Area under the whole blood concentration–time curve and peak concentration of cyclosporine
were increased by 55% and 35%, respectively, with grapefruit juice (P < .05). Seville orange juice had no
influence on cyclosporine disposition but reduced enterocyte concentrations of CYP3A4 by an average of
40%. 6¢ ,7¢ -Dihydroxybergamottin did not inhibit P-glycoprotein at concentrations up to 50 m mol/L.
Conclusions: 6¢ ,7¢ -Dihydroxybergamottin is not responsible for the effects of grapefruit juice on cyclosporine.
Because the interaction did not occur with Seville orange juice despite reduced enterocyte concentrations
of CYP3A4, inhibition of P-glycoprotein activity by other compounds in grapefruit juice may be responsi-
ble. Reduced enterocyte CYP3A4 by 6¢ ,7¢ -dihydroxybergamottin could be important for other drugs whose
bioavailability is less dependent on P-glycoprotein. (Clin Pharmacol Ther 1999;65:237-44.)
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PHARMACOKINETICS AND
DRUG DISPOSITION
The ingestion of grapefruit juice increases the oral
bioavailability of a number of drugs, including felodi-
pine, nifedipine, midazolam, triazolam, terfenadine,
and cyclosporine (INN, ciclosporin).1-11 All of these
drugs are metabolized by CYP3A4, the predominant
cytochrome P450 enzyme in the gut wall and liver.12
Grapefruit juice has no effect on drug disposition after
intravenous administration2,9,10 and does not alter liver
CYP3A4 activity as measured by the erythromycin
breath test.11 This suggests that drug bioavailability is
altered through an effect on intestinal CYP3A4. Sup-
port for this hypothesis comes from experiments that
show that grapefruit juice reduces the activity of
CYP3A in vitro13 and from clinical studies in which a
rapid decrease in the enterocyte concentration of
CYP3A4 has been observed after drinking juice.11,14
In a recent study of stable kidney transplant patients,
Lown et al15 reported that intestinal P-glycoprotein was
a more important determinant of the oral bioavailabil-
ity of cyclosporine than intestinal CYP3A4. P-Glyco-
protein is a transmembrane protein involved in drug
efflux from the enterocyte back into the intestinal
lumen. This suggests that grapefruit juice may increase
cyclosporine availability through an effect on P-glyco-
protein rather than or in addition to an effect on
CYP3A4.
The possibility that the clinical effects of grapefruit
juice are mediated through a mechanism other than
inhibition of CYP3A4 could explain the lack of suc-
cess to date in identifying the compound or compounds
responsible. Flavonoids such as naringin and quercetin
inhibit CYP3A4 in vitro,16,17 but direct administration
to humans failed to reproduce the effects of grapefruit
juice on felodipine and nifedipine.18,19 Several fura-
nocoumarins including 6 ¢ ,7 ¢ -dihydroxybergamottin
have been isolated from grapefruit juice and identified
as potent inhibitors of CYP3A4 in vitro.14,20-22 6 ¢ ,7 ¢ -
Dihydroxybergamottin is present in significant concen-
tration in grapefruit juice (10 to 60 m mol/L), is a mech-
anism-based inhibitor of CYP3A activity, and reduces
the concentration of immunoreactive CYP3A4 when
added to CACO-2 cell culture, mimicking the effects
of grapefruit juice in vivo.14 Juice prepared from Seville
oranges also contains this compound in concentrations
comparable to those found in grapefruit juice and has
similar inhibitory activity against CYP3A4 in vitro.13
Is 6 ¢ ,7 ¢ -dihydroxybergamottin responsible for the
effects of grapefruit juice on cyclosporine disposition?
What effect does 6 ¢ ,7 ¢ -dihydroxybergamottin have on
enterocyte CYP3A4 and P-glycoprotein activity? The
studies described in this report were designed to address
these questions. 6 ¢ ,7 ¢ -Dihydroxybergamottin is not
available in sufficient quantity for administration to
humans. Therefore the disposition of oral cyclosporine
was compared after administration of Seville orange
juice and grapefruit juice to healthy volunteers. To
study the effect of 6 ¢ ,7 ¢ -dihydroxybergamottin on en-
terocyte CYP3A4, enzyme concentrations were mea-
sured in 2 individuals before and after ingestion of
Seville orange juice. Finally, in vitro experiments were
conducted to assess the effect of 6 ¢ ,7 ¢ -dihydroxyberg-
amottin on P-glycoprotein function.
METHODS
Subjects. Seven healthy volunteers (5 men and 2
women), ranging in age from 23 to 41 years old (mean
age, 30 years), completed the pharmacokinetic study.
All individuals were nonsmokers, within 20% of ideal
body weight (80.0 ± 12.1 kg), and refrained from alco-
hol and medications, including over-the-counter drugs,
throughout the study. In addition, they were instructed
not to ingest any product that contained grapefruit start-
ing 1 week before the first study day and continuing
throughout the study.
Study design. A randomized crossover study design
was used in which subjects received a single oral dose of
7.5 mg/kg cyclosporine (Sandimmune soft gelatin cap-
sules; Sandoz) with water, grapefruit juice, and Seville
orange juice. Each treatment was separated by a 1-week
washout period. After an overnight fast, subjects ingested
8 ounces of water or juice 30 minutes before administra-
tion of cyclosporine and 31⁄2, 71⁄2, and 111⁄2 hours after the
cyclosporine dose. Standard meals were served at 4 and
10 hours after dosing. Blood samples (5 mL) were col-
lected at 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours into tubes
that contained ethylenediaminetetraacetic acid and the
samples frozen at –20°C pending analysis.
Grapefruit juice and Seville orange juice. Grapefruit
juice was prepared by reconstituting frozen concentrated
juice (Old South, Lykes Pasco, Inc, Dade City, Florida)
to regular strength. Seville orange juice was prepared
by squeezing fresh fruit. The juice was then frozen at
–20°C until needed for the study (less than 6 weeks).
The concentration of 6 ¢ ,7 ¢ -dihydroxybergamottin in
grapefruit juice and Seville orange juice was measured
by HPLC20 and was comparable at a concentration of
approximately 30 m mol/L.
Cyclosporine sample and data analysis. Whole
blood samples were assayed within 4 weeks of collec-
tion with use of a monoclonal radioimmunoassay spe-
cific for cyclosporine (CYCLO-Trac SP-Whole Blood;
Incstar Corporation, Stillwater, Minn). Within-day and
between-day variability for control samples was
between 5% and 10%. The limit of quantitation was 20
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ng/mL. Area under the whole blood concentration–time
curve (AUC) was calculated with the linear trapezoidal
rule. Peak cyclosporine concentration (Cmax) and the
time to reach the peak concentration (tmax) were
obtained directly from the data. Statistical analysis
was performed with SYSTAT for Windows, V5.03
(SYSTAT Inc, Evanston, Ill). ANOVA was used to exam-
ine differences between the groups with post hoc analy-
sis with use of contrast testing (P < .05 for significance).
Effect of Seville orange juice on enterocyte
CYP3A4 concentration. Two individuals from the
pharmacokinetic study (subjects 1 and 2) participated
in a separate study in which enterocyte CYP3A4 con-
centrations were measured before and after treatment
with Seville orange juice. No medications or citrus
products were taken for 1 week before the study. After
fasting for approximately 4 hours, subjects were
sedated with midazolam and meperidine (INN, pethi-
dine). A fiberoptic endoscope was passed into the duo-
denum where biopsy samples were collected. Begin-
ning the following morning and during the next 48
hours, subjects ingested 8 ounces of Seville orange
juice on 5 occasions (8 AM, 2 PM, 8 PM, 8 AM, and 2 PM).
The duodenal biopsy was repeated 4 hours after the
final glass of Seville orange dose. Biopsy specimens
were assayed for CYP3A4, P-glycoprotein, and villin
concentration by immunoblotting as described previ-
ously.11 To exclude the possibility that 6 ¢ ,7 ¢ -
dihydroxybergamottin interacts with CYP3A4 so that
the enzyme is still functional but no longer reacts with
the antibody used for immunoblotting, 6¢ ,7¢ -dihydroxy-
bergamottin was incubated with human intestinal
microsomes in the presence of NADPH. The reaction
was stopped at intervals up to 30 minutes, and the mix-
ture was diluted 100-fold with buffer. CYP3A4 activ-
ity was measured as the rate of metabolism of
saquinavir,23 and immunoblots were prepared to assess
the reactivity of CYP3A4 to the antibody.
Effect of 6´,7´-dihydroxybergamottin on P-glycopro-
tein activity in vitro. P-glycoprotein activity was
assessed with a microfluorometric calcein-AM assay and
by examining the transport of 3H-vinblastine in cultured
cells.24-27 LLC-PK1 pig kidney epithelial cells were
obtained from American Type Culture Collection
(Rockville, Md) and cultured.24 LLC-PK1 derivative cell
lines that contained human MDR1 (L-MDR1) were pro-
vided by Dr Alfred Schinkel (The Netherlands Cancer
Institute, Amsterdam). Cells were cultured in Costar 96-
well plates on day 0 at 100,000 cells/well in phenol red
indicator free medium. On day 1, medium was removed
and the well washed once with 200 m L Hanks buffer
(Life Technologies). One hundred microliters Hanks
buffer with or without 6 ¢ ,7 ¢ -dihydroxybergamottin was
added and the cells incubated for 15 minutes at 37°C.
One hundred microliters of Hanks buffer containing cal-
cein-AM (2 m mol/L; Molecular Probes, Eugene, Ore)
was added to reach a final concentration of 1 m mol/L.
The plates were scanned at 3-minute intervals during a
33-minute period with a fluorescence microplate reader
(Cytofluor 2350; Millipore) with excitation and emis-
sion wavelengths set at 485 and 530 nm. The rate con-
stant for reversal of calcein-AM accumulation (ki) was
estimated with a modified form of the Michaelis-Menten
equation.25
Assessment of the transport of 3H-vinblastine was
performed as described previously.24 In brief, cells were
plated on day 0 at 2 · 106 cells/well in Transwell dishes
(Costar 3414) that contained 2 mL medium in each com-
partment. On day 3, cells were washed and medium with
or without 6¢ ,7¢ -dihydroxybergamottin (5 or 10 m mol/L)
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Table I. Pharmacokinetics of cyclosporine administered with water, grapefruit juice, or Seville orange juice
AUC (ng · hr/mL) Cmax (ng/mL)
Grapefruit Seville orange Grapefruit Seville orange
Subject No. Gender Water juice juice Water juice juice
1 Male 6,561.4 13,190.0 8,419.0 1,114.0 1,666.0 1,197.0
2 Female 3,220.5 5,415.0 5,157.0 875.0 916.0 367.0
3 Male 7,866.0 13,586.5 7,875.0 689.0 1,481.0 1,043.0
4 Male 6,022.5 6,383.5 6,861.0 1,275.0 1,183.0 1,129.0
5 Female 8,311.0 10,289.5 7,302.5 1,096.0 1,300.0 462.0
6 Male 5,035.5 12,434.0 5,640.0 875.0 1,468.0 965.0
7 Male 11,800.5 14,336.5 7,616.0 1,688.0 2,289.0 1,407.0
Mean 6,973.9 10,805.0* 6,981.5 1,087.4 1,471.8* 938.6
SD 2,732.5 3,592.1 1,191.2 328.0 433.5 384.7
AUC, Area under the whole blood concentration–time curve; Cmax, peak cyclosporine concentration.
*Significantly different from both other treatments (P < .05).
was added to both apical and basal compartments and
preincubated for 1 hour at 37°C. 3H-Vinblastine was
added to a final concentration of 2 m mol/L to either the
apical or basal compartment. Fifty-microliter aliquots
were obtained hourly for 4 hours from the opposite com-
partment to which vinblastine was added, the samples
were counted, and the results were expressed as the per-
centage of total radioactivity appearing in the opposite
compartment.
RESULTS
The pharmacokinetic parameters for cyclosporine
when given with water, grapefruit juice, and Seville
orange juice are summarized in Table I. The average
AUC was increased by 55% with grapefruit juice com-
pared with water (P < .05). Cmax was also significantly
increased with grapefruit juice. No statistically signifi-
cant differences were observed in these parameters
between water and Seville orange juice. The tmax was
similar when cyclosporine was given with water (3.7 ±
2.9 hours) and grapefruit juice (3.4 ± 1.1 hours). When
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Figure 1. Blood concentration–time profile for cyclosporine
in subject 1 after ingestion of cyclosporine with water, grape-
fruit juice, or Seville orange juice.
Figure 2. Immunoblots of enterocyte concentration of
P-glycoprotein, villin, and CYP3A4 in healthy subjects dur-
ing control conditions (Pre) and after ingestion of Seville
orange juice (Post).
Figure 3. CYP3A4 activity and concentration of immuno-
reactive protein in intestinal microsomes after incubation with
6 ¢ ,7 ¢ -dihydroxybergamottin (DHB) for up to 30 minutes. The
loss of catalytic activity (saquinavir metabolism) reflects the
extent of irreversible inhibition because microsomes were
diluted 100-fold before the assay.
Figure 4. Microfluorometric evaluation of P-glycoprotein
inhibition by 6 ¢ ,7 ¢ -dihydroxybergamottin (DHB). LLC-PK1
(open squares) and L-MDR1 cells were incubated in the
absence (solid circles) or presence of 5 m mol/L (triangles), 10
m mol/L (open circles), and 50 m mol/L (solid squares) 6 ¢ ,7 ¢ -
dihydroxybergamottin for 15 minutes. Calcein-AM, 1 m mol/L,
was added and fluorescence of calcein was monitored spec-
trofluorometrically for 30 minutes. Each data point represents
the mean ± SD of 4 to 6 independent measurements.
administered with Seville orange juice, the absorption
of cyclosporine was delayed in some subjects (9.0 ± 7.7
hours). The cyclosporine blood concentration–time pro-
file for subject 1 is shown in Figure 1. The profile in
this subject is representative in that AUC and Cmax are
elevated with grapefruit juice, whereas no differences
are apparent between water and Seville orange juice.
Subjects 1 and 2 underwent duodenal biopsy before
and after ingestion of Seville orange juice to examine
the effect on the enterocyte concentration of CYP3A4
and P-glycoprotein. The results are presented in Figure
2. The concentration of CYP3A4 was clearly decreased
after Seville orange juice treatment. CYP3A4 concen-
tration declined by 35% in subject 1 and by 45% in sub-
ject 2. No consistent change in the concentration of
P-glycoprotein or villin was observed with Seville
orange juice treatment. Irreversible inactivation of
CYP3A4 by 6 ¢ ,7 ¢ -dihydroxybergamottin in vitro was
confirmed by a significant decrease in the rate of metab-
olism of saquinavir, whereas the enzyme retained the
ability to interact with the antibody (Figure 3).
The effect of 6¢ ,7¢ -dihydroxybergamottin on P-glyco-
protein activity as measured by the intracellular concen-
tration of calcein is illustrated in Figure 4. P-Glycopro-
tein removes calcein-AM from the cell before its con-
version to the fluorescent metabolite calcein in the
cytosol. Cells lacking P-glycoprotein (LLC-PK1) attain
high intracellular calcein concentrations, whereas cells
expressing P-glycoprotein (L-MDR1) have little intra-
cellular calcein.26,27 Cotreatment of L-MDR1 cells with
a P-glycoprotein inhibitor should increase intracellular
calcein. A 15-minute preincubation of LLC-PK1 cells
with 6¢ ,7¢ -dihydroxybergamottin at concentrations up to
50 m mol/L had no effect on calcein fluorescence (data
not shown), indicating that the compound had no non-
specific effects on membrane integrity, calcein fluores-
cence, or conversion of calcein-AM to calcein. 6 ¢ ,7 ¢ -
Dihydroxybergamottin at concentrations of 5 and 10
m mol/L had no effect on calcein concentrations in
L-MDR1 cells and at 50 m mol/L caused only an 8.8%
increase (Figure 4). The estimated ki for reversal of cal-
cein-AM accumulation was 519.6 m mol/L for 6¢ ,7¢ -dihy-
droxybergamottin. In these same cells, values of 4.66
and 5.78 m mol/L were obtained for the classic P-glyco-
protein inhibitors cyclosporine and amiodarone, respec-
tively (data not shown). 6 ¢ ,7 ¢ -Dihydroxybergamottin
also had no effect on the flux of 3H-vinblastine in either
direction across the LLC-PK1 cells (Figure 5). As
expected, cyclosporine increased apical to basolateral
flux while it inhibited basolateral to apical movement
of vinblastine across L-MDR1 cells (data not shown).
DISCUSSION
Grapefruit juice increases the oral bioavailability of
a number of drugs subject to metabolism by CYP3A4
but appears to have little or no effect on the disposition
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Figure 5. Effect of 6 ¢ ,7 ¢ -dihydroxybergamottin on the transepithelial transport of 3H-vinblastine
across L-MDR1 cells. Cells were preloaded in both compartments for 1 hour with either 5 m mol/L
or 10 m mol/L 6 ¢ ,7 ¢ -dihydroxybergamottin and the assay started by adding 3H-vinblastine to either
the apical or basal compartment and sampling the opposite compartment at the indicated times.
Each data point represents the mean ± SD of 3 to 4 independent measurements.
of such drugs after intravenous administration. Reduced
gut wall metabolism is consistent with the observation
that enterocyte CYP3A4 protein concentration is
reduced after ingestion of grapefruit juice.11,14 We have
suggested that 6 ¢ ,7 ¢ -dihydroxybergamottin, a furano-
coumarin identified and isolated from grapefruit juice
on the basis of its ability to inhibit CYP3A in vitro,12,20
could be the main substance responsible for the inter-
actions between drugs and grapefruit juice. 6¢ ,7 ¢ -Dihy-
droxybergamottin is a mechanism-based or suicide
inhibitor of CYP3A4,14 a characteristic that it shares
with other furanocoumarins, including bergamottin,
8-methoxypsoralen (methoxsalen) and 5-methoxy-
psoralen (bergapten).22,28-30 Incubation of 6 ¢ ,7 ¢ -
dihydroxybergamottin with CACO-2 intestinal cells
that express CYP3A4 reproduces the decrease in
CYP3A4 concentration observed when grapefruit juice
is administered to human subjects.14
Although there is strong evidence to support the con-
tention that 6 ¢ ,7 ¢ -dihydroxybergamottin reduces
CYP3A4 activity in the intestine, recent studies have
suggested that gut metabolism may not be the primary
factor that limits the oral bioavailability of cyclosporine.
Lown et al15 measured intestinal concentrations of both
P-glycoprotein and CYP3A4 in 19 patients receiving
oral cyclosporine after kidney transplantation. A signif-
icant correlation was observed between intestinal
P-glycoprotein content and the oral clearance of
cyclosporine, but no relationship was observed with
intestinal CYP3A4 content. Cyclosporine is transported
by human P-glycoprotein,31 and Fricker et al32 found
that the absorption of cyclosporine after administration
at different sites in the gastrointestinal tract was highly
correlated with the quantity of P-glycoprotein messen-
ger ribonucleic acid (mRNA) at that site. P-Glycopro-
tein is the product of the multidrug resistance gene
(MDR1) and is a transmembrane protein (170 kd) found
in a number of normal tissues, including the intestine.33
It acts to prevent the entry of foreign compounds into
the systemic circulation by extruding lipophilic mole-
cules from the enterocyte back into the intestinal lumen.
This protective function is shared with cytochrome P450
enzymes such as CYP3A4, and many compounds have
been identified as substrates or inhibitors of both
CYP3A4 and P-glycoprotein.34-37
If the oral bioavailability of cyclosporine is primar-
ily a function of P-glycoprotein activity, how does
grapefruit juice increase blood concentrations of
cyclosporine? This question was addressed by admin-
istration of cyclosporine with grapefruit juice and
Seville orange juice that contained comparable amounts
of 6 ¢ ,7 ¢ -dihydroxybergamottin. It would have been
preferable to administer 6 ¢ ,7 ¢ -dihydroxybergamottin
directly, but there is no known commercial source of
this compound. Small quantities sufficient for in vitro
studies can be synthesized or extracted from grapefruit
juice, but several hundred milligrams would have been
required to match the 6 ¢ ,7 ¢ -dihydroxybergamottin con-
tent of the administered grapefruit juice. We have pre-
viously found that 6 ¢ ,7 ¢ -dihydroxybergamottin is pre-
sent in juice prepared from Seville oranges, a sour
orange with limited commercial value, and that this
juice inhibits CYP3A activity in vitro to a similar
degree as grapefruit juice.12
Despite the presence of 6 ¢ ,7 ¢ -dihydroxybergamottin
in both juices, the data in Table I indicate that Seville
orange juice does not have the same effect on
cyclosporine disposition as grapefruit juice. Grapefruit
juice increased the mean AUC of cyclosporine from
6974 to 10,805 ng ·h/mL and mean Cmax from 1087 to
1472 ng/mL. This is in agreement with a previous study
conducted in our laboratory in which grapefruit juice
increased the AUC of orally administered cyclosporine
by about 60% from 6722 to 10,730 ng · h/mL, whereas
Cmax increased from 936 to 1340 ng/mL.9 Double peaks
in the absorption profile are not uncommon with
cyclosporine and were observed in many patients in both
of these studies. Seville orange juice had no significant
effect on either Cmax or AUC, although it appeared to
prolong or delay the absorption of cyclosporine in sev-
eral subjects. A comparison of the data for subject 1 pre-
sented in Figures 1 and 2 illustrates the contrast between
the effect of Seville orange juice on cyclosporine and
its effects on enterocyte concentrations of CYP3A4
(decreased by an average of 40%). The magnitude of
the effect is similar to the 47% reduction observed 4
hours after a single glass of grapefruit juice14 although
somewhat smaller than the 62% decrease reported with
8 ounces of grapefruit juice 3 times daily for 6 days.11
A potential explanation for these findings would be if
interaction with 6¢ ,7¢ -dihydroxybergamottin reduced the
ability of our antibody to recognize CYP3A4 but did
not alter the catalytic activity of the enzyme. However,
essentially complete irreversible inactivation of
CYP3A4 by 6 ¢ ,7 ¢ -dihydroxybergamottin did not affect
antibody reactivity with the enzyme in intestinal micro-
somes (Figure 3). This supports the idea that the loss of
CYP3A4 immunoreactive protein results from acceler-
ated degradation of the enzyme once it is irreversibly
inactivated by furanocoumarins.14
Because Seville orange juice and grapefruit juice
reduce intestinal CYP3A4 concentration but only grape-
fruit juice increases the oral bioavailability of
cyclosporine, it appears that the interaction is not pri-
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marily attributable to an effect on CYP3A4. Because P-
glycoprotein is known to play a significant role in
cyclosporine availability, it is reasonable to conclude that
grapefruit juice contains a compound or compounds that
inhibit P-glycoprotein activity. Although 6¢ ,7¢ -dihydroxy-
bergamottin may play a significant role in the effects of
Seville orange juice and grapefruit juice on enterocyte
CYP3A4, this furanocoumarin appears to have little
effect on human P-glycoprotein. The concentration of
P-glycoprotein was not affected by Seville orange juice
administration (Figure 2), and 2 separate in vitro mod-
els of P-glycoprotein function could not show any sig-
nificant effects of 6¢ ,7¢ -dihydroxybergamottin at typical
concentrations found in grapefruit juice (Figures 4 and
5). 6 ¢ ,7 ¢ -Dihydroxybergamottin may be somewhat
unique in its ability to inactivate CYP3A4 without affect-
ing P-glycoprotein function. Studies with well-known
inhibitors of CYP3A4, such as verapamil, ketoconazole,
and erythromycin, have documented that these com-
pounds also inhibit the activity of P-glycoprotein.34-37
Grapefruit juice contains numerous flavonoids and other
bioactive compounds that could affect P-glycoprotein
function. Although originally reported to have a stimu-
latory effect, a recent study showed that quercetin
strongly inhibited transport by P-glycoprotein.38
The results of this study suggest that 6¢ ,7¢ -dihydroxy-
bergamottin is not responsible for the clinical effects of
grapefruit juice on cyclosporine disposition and that
reduced metabolism of cyclosporine in the gut wall is
not the predominant mechanism for this interaction. It is
possible that the reduction in enterocyte CYP3A4 con-
tent produced by grapefruit juice and Seville orange juice
could be important in the interaction between grapefruit
juice and other drugs for which enterocyte CYP3A4 is a
more significant determinant of oral bioavailability. In
addition, inhibition of both P-glycoprotein function and
CYP3A4 activity may be required to produce the clini-
cal effects of grapefruit juice on some drugs. Further
studies are needed to identify inhibitors of P-glycopro-
tein in grapefruit juice and to evaluate the relative con-
tributions of reduced P-glycoprotein and CYP3A4 activ-
ity to the increased oral bioavailability of other drugs.
The ability of 6 ¢ ,7¢ -dihydroxybergamottin to selectively
inactivate CYP3A4 without affecting the function of P-
glycoprotein may prove to be a useful tool in studying
the mechanism by which these proteins limit systemic
exposure to xenobiotics.
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